Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：167

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 50 条

[1] eLEcTRA trial: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC)
Baumgaertner, A. K.
Fasching, P.
Paepke, S.
Kubista, E.
Barsoum, M.
Wallwiener, D.
Ragosch, V.
Aulitzky, W.
Prechtl, A.
Reimer, T.
Thomssen, C.
Jaenicke, F.
Harbeck, N.
Huober, J.
ONKOLOGIE, 2010, 33 : 7 - 8
[2] Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (MBC) - Results of the eLEcTRA Trial
Huober, J.
Fasching, P.
Paepke, S.
Kubista, E.
Barsoum, M.
Wallwiener, D.
Harbeck, N.
CANCER RESEARCH, 2009, 69 (24) : 737S - 738S
[3] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
Sun, Maoben
Cai, Liangzhen
Chen, Min
MEDICINE, 2023, 102 (24) : E33975
[4] Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report
Suwanvecho, Suthida
Kiatikajornthada, Narongsak
Phikulsod, Ployploen
Suwanrusme, Harit
Jirawatnotai, Siwanon
CASE REPORTS IN ONCOLOGY, 2025, 18 (01): : 130 - 136
[5] Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib
Sherrill, Beth
Sherif, Bintu
Amonkar, Mayur M.
Maltzman, Julie
O'Rourke, Lisa
Johnston, Stephen
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (12) : 2245 - 2252
[6] Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Doss, Sally
Robertson, Janet
Adam, Jane
LANCET ONCOLOGY, 2012, 13 (08): : 766 - 767
[7] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
Beom, Seung Hoon
Oh, Jisu
Kim, Tae-Yong
Lee, Kyung-Hun
Yang, Yaewon
Suh, Koung Jin
Moon, Hyeong-Gon
Han, Sae-Won
Oh, Do-Youn
Han, Wonshik
Kim, Tae-You
Noh, Dong-Young
Im, Seock-Ah
CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463
[8] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Del Mastro, Lucia
Lambertini, Matteo
Bighin, Claudia
Levaggi, Alessia
D'Alonzo, Alessia
Giraudi, Sara
Pronzato, Paolo
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
[9] OUR TREATMENT STRATEGY FOR PATIENTS WITH HORMONE-RECEPTOR-POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER
Tanaka, Haruo
Umeda, Shuyo
Murakami, Souichiro
Ishikawa, Mikimasa
Tanaka, Kimiharu
Uchiyama, Akihiko
BREAST, 2015, 24 : S51 - S51
[10] Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
Shagisultanova, Elena
Diamond, Jennifer
Stopeck, Alison
Pusztai, Lajos
O'Regan, Ruth
Gradishar, William
Brown-Glaberman, Ursa
Chalasani, Pavani
McSpadden, Tessa
Borakove, Michelle
Shedin, Troy
Kabos, Peter
Borges, Virginia
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →